# A Study of ADRX-0706 in Select Advanced Solid Tumors

> **NCT06036121** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Adcentrx Therapeutics** · enrollment: 144 (estimated)

## Conditions studied

- Solid Tumors
- Triple Negative Breast Cancer (TNBC)
- Urothelial Cancer
- Cervical Cancer

## Interventions

- **DRUG:** ADRX-0706

## Key facts

- **NCT ID:** NCT06036121
- **Lead sponsor:** Adcentrx Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2025-09
- **Final completion:** 2026-12
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06036121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06036121, "A Study of ADRX-0706 in Select Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06036121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*